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Background: We previously described the visceral antinociceptive property of α-bisabolol (BISA) in mouse models
of visceral nociception induced by cyclophosphamide and mustard oil (MO). This study examined the effect of BISA
in mouse models of visceral nociception induced by acetic acid, capsaicin, formalin, and the contribution of the
nitric oxide system, α2, KATP+, 5-HT3 and TRPV1 receptors to the effect of BISA on MO-evoked nociceptive behaviors.
Mice were pretreated orally with BISA (50, 100 and 200 mg/kg) or vehicle, and the pain-related behavioral
responses to intraperitoneal administration of acetic acid or intracolonic injection of MO were analyzed.
Results: BISA significantly suppressed the nociceptive behaviors in a dose-unrelated manner. The antinociceptive
effect of BISA (50 mg/kg) was show to be glibenclamide resistant, but it was not blocked by pretreatment with the
other antagonists tested. In the open-field test that detects sedative or motor abnormality, mice received 50 mg/kg
BISA did not show any per se influence in ambulation frequency.
Conclusions: However, their precise antinociceptive mechanisms of action have not been determined.
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Essential oils are natural products that exhibit a variety of
biological properties such as analgesic, anticonvulsant, and
anxiolytic ones. Such effects are often attributed to the
presence of monoterpenes, which are the major chemical
components of these oils [1]. Sesquiterpenes, such zerum-
bone [2], budlein A [3], polygodial [4], and lapidin [5], have
been shown to present antinociceptive properties.
Recent studies demonstrated that the sesquiterpene α-
bisabolol (BISA) presents antitumor [6], peripheral ner-
vous blocker [7], gastroprotective [8], leishimanicidal [9],
antioxidant [10], mutagenic and antimutagenic [11], and
wound healing [12] properties. There are also evidences
showing that BISA reduced visceral nociceptive pain
evoked by intracolonic administration of mustard oil
(MO) as well as that induced by intraperitoneal injection
of cyclophosphamide, possibly involving the inhibition of
sensitization of primary afferent neuron terminals by
prostaglandins [13].* Correspondence: adrirolim@unifor.br
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in any medium, provided the original work is pHowever, the mechanisms underlying these antinoci-
ceptive properties of BISA are not well understood.
Methods
Animals
Male Swiss albino mice (20–25 g) obtained from the
Central Animal House of Regional University of Cariri
were used. They were housed in environmentally con-
trolled conditions (22°C, 12-h light–dark cycle), with
free access to standard pellet diet (Purina, São Paulo,
Brazil) and water. Animals were kept in cages with
raised floors to prevent coprophagy. Before the visceral
antinociceptive assays, they were fasted over a period of
15 h and were habituated to the test environment for 2
h before the experimentation. The experimental proto-
cols were in accordance with the ethical guidelines of
National Institute of Health, Bethesda, USA. The studies
were performed in a blinded manner.
Acetic acid-induced visceral nociception
Abdominal constrictions were induced by intraperitoneal
injection of acetic acid (0.6%). The animals were pre-
treated with BISA (50, 100 or 200 mg/kg, p.o.) or vehicleOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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acid injection. After the challenge, each mouse was
placed in a separate glass funnel and the number of
contractions of the abdominal muscles, together with
stretching, was cumulatively counted over a period of
20 min. Antinociceptive activity was expressed as the
reduction in the number of abdominal contractions,
comparing the control animals with the mice pre-
treated with BISA.Capsaicin-induced visceral nociception
Male mice divided into groups of eight in each were pre-
treated with the vehicle (2% Tween 80 in distillated water,
10 mL/kg, p.o.) or BISA (50, 100 or 200 mg/kg, p.o.). 1 h
after oral and 30 min following systemic treatments, cap-
saicin (0.3% in a solution of PBS:Tween 80:ethanol (8:1:1))
was instilled into the colon (50 μL/animal) using a fine
cannula (1.6-mm external diameter), 4-cm far from the
anal sphincter. Solid petroleum jelly was applied onto
the perianal region to avoid local nerve stimulation. The
animals were then observed during a 30-min period for
the spontaneous visceral pain-related behaviors (licking
the upper abdomen, abdominal contortion and retrac-
tion, squashing the abdomen against the floor). A nor-
mal group, that received only saline intracolonically, was
also included.Formalin-induced visceral nociception
Male mice divided into groups of eight in each were pre-
treated with the vehicle (2% Tween 80 in distillated water,
10 mL/kg, p.o.) or BISA (50, 100 or 200 mg/kg, p.o.). 1 h
after oral and 30 min following systemic treatments, for-
malin (10%) was instilled into the colon (10 μL/animal)
using a fine cannula (1.6-mm external diameter), 4-cm far
from the anal sphincter. Solid petroleum jelly was applied
onto the perianal region to avoid local nerve stimulation.
The animals were then observed during a 60-min period
for the spontaneous visceral pain-related behaviors (licking
the upper abdomen, abdominal contortion and retraction,
squashing the abdomen against the floor). A normal group,
that received only saline intracolonically, was also included.Table 1 Antinociceptive effect of BISA in capsaicin, formalin,
Group Dose (mg/kg) Specific behaviors
Capsaicin For
Normal - 10.25 ± 6.21** 198
Vehicle - 84.38 ± 12.99 344
BISA 50 87.00 ± 19.30 103
100 31.00 ± 13.11** 140
200 15.33 ± 10.82** 75.
Values represent the mean ± SEM of pain-related behaviors (licking of abdomen, st
(ANOVA, Student-Newman-Keul’s test).MO-induced visceral nociception
To assess the antinociceptive effect of BISA against the
MO-induced visceral nociception, mice in groups (n = 8)
were orally treated with BISA (50, 100 or 200 mg/kg, p.o.)
or vehicle (2% Tween 80 in distillated water, 10 mL/kg,
p.o.) 1 h before the intracolonic administration of
MO (0.75% in saline 0.9%, 50 μL/animal). A group of
normal control received a similar dose of saline (10 mL/kg).
Immediately following the intracolonic MO or saline
administration, the mice were observed for the total
number of nociceptive behaviors (licking the upper
abdomen, stretching the abdomen, squashing the ab-
domen against the floor and retraction of the abdo-
men characterized for an arched position), for a 20-min
period.
In order to verify the possible involvement of nitrergic,
noradrenergic, KATP
+, 5-HT3, and TRPV1 receptors in the
effect of BISA, the animals were treated with L-NAME
(10 mg/kg, i.p), yohimbine (2 mg/kg, i.p), glibenclamide
(5 mg/kg, i.p), ondansetron (10 mg/kg, i.p) or ruthenium
red (3 mg/kg, s.c.), 30 min before the administration of
BISA (50 mg/kg).
Locomotor activity (open-field test)
The open-field area was made of acrylic (transparent
walls and black floor: 30 × 30 × 15 cm2) divided in nine
squares of equal area. Four groups of animals (n = 6)
were used. While groups 1 and 2 were treated, respect-
ively, with vehicle (2% Tween 80, 10 mL/kg, p.o.) and
BISA (50 mg/kg, p.o.), groups 3 and 4 received vehicle +
MO (0.75%, 50 μL) or BISA (50 mg/kg, p.o.) + MO. The
MO was given by an intracolonic route 90 following the
vehicle or BISA. The numbers of squares each animal
crossed with the four paws were noted during a 4-min
period.
Statistical analysis
The results are expressed as mean ± SEM from six or
eight mice per group. For statistical analysis, ANOVA
followed by Tukey’s or Student–Newman–Keul’s post
hoc test, as appropriate, were used. A p < 0.05 was con-
sidered statistically significant.MO, and acetic acid-induced visceral nociception in mice
malin MO Acetic acid
.60 ± 47.87** 21.57 ± 7.13*** -
.60 ± 50.21 107.80 ± 25.01 48.63 ± 10.81
.00 ± 16.21*** 21.67 ± 7.99*** 10.50 ± 2.94***
.40 ± 25.51*** 33.83 ± 10.28*** 8.50 ± 3.20***
13 ± 13.44*** 27.17 ± 11.05*** 8.43 ± 2.57***
retching, abdominal retractions). **p < 0.01 and ***p < 0.001 versus vehicle
Table 2 Effect of yohimbine, ondansetron, L-NAME,
glibenclamide and ruthenium red against MO-induced
visceral pain in mice
Group Dose (mg/kg) Specific behaviors
Normal - 18.14 ± 3.44*
Vehicle - 44.17 ± 5.59
Yohimbine 2 22.28 ± 3.53*
Ondansetron 0.5 44.75 ± 5.89
L-NAME 20 27.13 ± 3.74
Glibenclamide 5 40.88 ± 8.39
Ruthenium red 0.3 29.25 ± 4.98
Values represent the mean ± SEM of pain-related behaviors (licking of
abdomen, stretching, abdominal retractions). *p < 0.05 versus vehicle (ANOVA,
Student-Newman-Keul’s test).
Table 4 Evaluation of involvement of serotonergic,
nitrergic, KATP
+ channels, and TRPV1 receptors in the
antinociceptive effect of BISA in MO test
Group Dose (mg/kg) Specific behaviors
Normal - 88.25 ± 18.59**
Vehicle - 181.90 ± 24.07
BISA 50 115.70 ± 25.33*
BISA + Ondansetron 50 + 0.5 57.13 ± 11.07***
BISA + L-NAME 50 + 20 31.25 ± 8.64***
BISA + glibenclamide 50 + 5 86.57 ± 15.61*
BISA + ruthenium red 50 + 3 61.71 ± 8.41**
Values represent the mean ± SEM of pain-related behaviors (licking of
abdomen, stretching, abdominal retractions). *p < 0.05, **p < 0.01 and ***p <
0.001 versus vehicle (ANOVA, Student-Newman-Keul’s test).
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Effect of BISA on acetic acid, capsaicin, formalin and
MO-induced visceral pain in mice
Table 1 shows the antinociceptive effect of BISA in
acetic acid, capsaicin, formalin and MO. Intraperitoneal
application of acetic acid (0.6%) provoked a significant
increase in abdominal constrictions when compared
with saline-treated normal control. In groups pretreated
with BISA (50, 100 and 200 mg/kg, p.o.), acetic acid-
induced abdominal constrictions were significantly
inhibited in a dose-unrelated manner. Intracolonic appli-
cation of capsaicin (CAP 0.3%), MO (MO 0.75%), or for-
malin (10%) provoked a significant increase in
spontaneous pain-related behaviors when compared with
saline-treated normal controls (Table 1). In groups pre-
treated with BISA, capsaicin, formalin and MO-
induced nociceptive behaviors were significantly inhib-
ited. L-NAME, yohimbine, glibenclamide, ondansetron,
or ruthenium red failed to revert the antinociceptive
effect of BISA (Tables 2, 3 and 4). Table 5 shows the
effects of orally administered BISA on behavior in
open-field test in mice. At the dose tested (50-mg/kg),
BISA showed no significant influence on the number
of crossings in open-field test.
In this study, we observed that the acetic acid, capsa-
icin, formalin, and MO-evoked nociceptive pain beha-
viors were significantly attenuated in mice pretreatedTable 3 Effect of α2-adrenoceptor antagonism on the
antinociceptive effect of BISA in MO test
Group Dose (mg/kg) Specific behaviors
Normal - 4.25 ± 1.77***
Vehicle 28.50 ± 4.00
BISA 50 1.29 ± 0.75***
BISA + yohibmine 50 + 2 5.75 ± 1.77***
Values represent the mean ± S.E.M. of pain-related behaviors (licking of
abdomen, stretching, abdominal retractions). ***p < 0.001 vs Vehicle (ANOVA,
Student-Newman-Keul’s test).with BISA, a natural sesquiterpenoid isolated from the
different essential oils. It has been well established that
many algogenic substances induce nociceptive pain-
related behaviors in rodents following intraperitoneal or
intracolonic application, and several reports reveal that
naturally occurring compounds, like terpenoids, unsatur-
ated dialdehydes and phenolic ketones can suppress
these behaviors [14].
Many studies use acetic acid-induced effects as a
model of visceral nociception but it lacks specificy [15].
Capsaicin, the pungent ingredient of red peppers applied
topically or injected into the skin of humans or experi-
mental animals, is known to stimulate the vanilloid re-
ceptor (Transient Receptor Potential cation channel V1
or TRPV1) located on polymodal C-fibers, but also in
other tissues and initiates a complex cascade of events,
including neuronal excitation and release of pro-
inflammatory mediators, desensitization of receptor, and
neuronal toxicity [16,17]. The intracolonic instillation of
formalin via the anus evokes differentiated behaviors,
which reflect visceral nociception. All types of behavior
were dose dependently inhibited by morphine, indicating
that they are pain-related [18]. As shown before, BISA
could significantly suppress the nociception-related
behaviors against MO-induced visceral nociception [13].
Visceral pain is a prominent form of pain in many
clinical conditions [15]. The results obtained in theTable 5 Effect of BISA on mouse behavior in open-field test
Group Number of crossings
Vehicle 23.50 ± 5.04
BISA 13.57 ± 3.22
Vehicle + MO 31.86 ± 5.06
BISA + MO 19.00 ± 5.27
Mice were pre-treated with vehicle (2% Tween 80 in distilled water, p.o.) or
BISA 50 mg/kg (p.o.), before intracolonic instillation of saline or MO (0.75%,
50 μL). Data represent mean ± SEM (n = 8). Data represent the mean ± SEM
(n = 8). ANOVA, Student-Newman-Keul’s test).
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models of visceral nociception are shown in Table 1. In
vehicle-treated control groups of mice, acetic acid-,
capsaicin-, formalin-, and MO-induced spontaneous
nociception-related behaviors when compared with
respective saline-treated control groups. In groups
pretreated with BISA, the nociceptive behaviors induced
by algogenic substances were significantly inhibited in a
dose-independent manner.
In the search of the possible action mechanism of
BISA, we used the acute model of visceral nociception
induced by intracolonic instillation of MO, which has
disease relevancy to human irritable bowel syndrome
[18]. The sesquiterpene BISA could significantly sup-
press the pain-related behaviors against MO-induced
visceral nociception, possibly regulating the functioning
of primary afferent fibers. Visceral afferents express a
wide range of membrane receptors (including vanilloid
receptors, TRPV1) to chemical stimuli, which are
involved in sensory signaling from the gut to the central
nervous system [19]. When animals were pretreated with
BISA and ruthenium red (a non-competitive antagonist
of TRPV1) in combination, there was additive antinoci-
ception in MO test. Also, BISA 50 mg/kg failed to in-
hibit the visceral nociception induced by capsaicin.
These observations suggest that BISA does not act as a
TRPV1 agonist but may possibly induce a modulatory
influence on vanilloid-receptors, which needs further
clarification.
Previous studies have shown that MO can induce
acute colitis and BISA has been reported to exert antiin-
flammatory action [13,20]. Therefore, it is reasonable to
assume that BISA suppresses the inflammatory pain.
The α2-adrenoceptor agonist has been shown to induce
antinociceptive effect in the experimental model of
formalin-induced colitis in rats and reduce visceral
hypersensitivity in clinical settings [21,22]. Therefore, a
possible involvement of α2-adrenoceptors in the antino-
ciceptive effect of BISA in MO-model of visceral pain,
using the antagonist yohimbine was investigated. Yohim-
bine could not reverse the antinociception produced by
BISA, suggesting that α2-adrenoceptors play no role.
KATP
+ channel openers induce cell hyperpolarization, de-
crease the intracellular Ca2+ level and neurotransmitter re-
lease (calcitonin gene-related peptide and substance P),
that may account for antinociception [23,24]. To verify
such a possibility, we examined the effect of glibenclamide,
a blocker of KATP
+ channels on BISA antinociception. Pre-
treatment of mice with glibenclamide in combination with
BISA showed no alteration. When mice were pretreated
with L-NAME, a nitric oxide synthase inhibitor and the
5-HT3 antagonist, ondansetron, apparently a potentiated/
additive response which needs further analysis through an
isobolographic study.Drugs that impair motor activity or induce sedation
may give false-positive/negative results in nociceptive
tests. We therefore sought to verify such effects of BISA
on open-field test that detects motor incoordination
[25]. The sesquiterpene failed to alter significantly the
ambulation in open-field test. This result indicates that
BISA exerts analgesia without causing neurological or
muscular deficits.
Conclusions
Although BISA efficient diminished the acetic acid, cap-
saicin, formalin, and MO-evoked pain-related behaviors,
its mechanism is unclear from this study and future
studies are needed to verify how the sesquiterpene exerts
its antinociceptive action.
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